EA201991196A1 - Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов - Google Patents
Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментовInfo
- Publication number
- EA201991196A1 EA201991196A1 EA201991196A EA201991196A EA201991196A1 EA 201991196 A1 EA201991196 A1 EA 201991196A1 EA 201991196 A EA201991196 A EA 201991196A EA 201991196 A EA201991196 A EA 201991196A EA 201991196 A1 EA201991196 A1 EA 201991196A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diblo
- pegmema
- assembled
- self
- copolymers consisting
- Prior art date
Links
- 229920001577 copolymer Polymers 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000580 polymer-drug conjugate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/285—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
- C08F220/286—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
Abstract
Данное изобретение относится к конъюгатам полимер-лекарственное средство согласно формуле I и их применению для лечения заболеваний, таких как рак.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1619372.4A GB2556055B (en) | 2016-11-16 | 2016-11-16 | Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments |
PCT/IB2017/057155 WO2018092048A1 (en) | 2016-11-16 | 2017-11-16 | Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991196A1 true EA201991196A1 (ru) | 2020-02-12 |
Family
ID=60582632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991196A EA201991196A1 (ru) | 2016-11-16 | 2017-11-16 | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов |
Country Status (20)
Country | Link |
---|---|
US (1) | US20240108736A1 (ru) |
EP (2) | EP4242240A3 (ru) |
JP (2) | JP7208136B2 (ru) |
KR (2) | KR20230159714A (ru) |
CN (2) | CN117883590A (ru) |
AU (2) | AU2017362067B2 (ru) |
BR (1) | BR112019009656A2 (ru) |
CA (1) | CA3043577A1 (ru) |
DK (1) | DK3541427T3 (ru) |
EA (1) | EA201991196A1 (ru) |
ES (1) | ES2941790T3 (ru) |
FI (1) | FI3541427T3 (ru) |
GB (1) | GB2556055B (ru) |
HR (1) | HRP20230349T1 (ru) |
HU (1) | HUE061518T2 (ru) |
IL (1) | IL266593B (ru) |
MX (2) | MX2019005657A (ru) |
PL (1) | PL3541427T3 (ru) |
PT (1) | PT3541427T (ru) |
WO (1) | WO2018092048A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110124050B (zh) * | 2019-05-24 | 2022-05-24 | 西南大学 | 基于共价自组装策略的电荷翻转型聚合物载体的制备方法 |
CN110208498A (zh) * | 2019-07-17 | 2019-09-06 | 吉林大学 | 一种基于水分动态机理的土壤给水度原位测试方法 |
TR201911542A2 (tr) * | 2019-07-30 | 2021-02-22 | Bogazici Ueniversitesi | Anti̇kor-poli̇mer konjugatlari |
CN111116928B (zh) * | 2019-10-28 | 2021-11-12 | 西北工业大学 | 一种以双药物分子为基元的超分子超支化聚合物及制备方法 |
WO2021233549A1 (en) * | 2020-05-21 | 2021-11-25 | Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Anonim Sirketi | Cleavable polymer drug conjugates for viral diseases |
WO2023086949A1 (en) * | 2021-11-12 | 2023-05-19 | Northwestern University | Inflammation stimuli responsive peptide brush polymers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
EP2210616A1 (en) * | 2009-01-21 | 2010-07-28 | Centre National de la Recherche Scientifique | Multifunctional stealth nanoparticles for biomedical use |
WO2014152451A2 (en) * | 2013-03-14 | 2014-09-25 | University Of Rochester | Compositions and methods for controlled localized delivery of bone forming therapeutic agents |
CN106029059A (zh) * | 2013-10-07 | 2016-10-12 | 康涅狄格大学 | 用于药品递送的自组装刷状嵌段共聚物-纳米颗粒 |
US10709791B2 (en) * | 2014-11-12 | 2020-07-14 | University Of Washington | Stabilized polymeric carriers for therapeutic agent delivery |
GB2551979A (en) * | 2016-06-30 | 2018-01-10 | Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd | Cleavable polymer drug conjugates |
-
2016
- 2016-11-16 GB GB1619372.4A patent/GB2556055B/en active Active
-
2017
- 2017-11-16 HU HUE17809387A patent/HUE061518T2/hu unknown
- 2017-11-16 EP EP23150565.2A patent/EP4242240A3/en active Pending
- 2017-11-16 CN CN202410032659.9A patent/CN117883590A/zh active Pending
- 2017-11-16 EA EA201991196A patent/EA201991196A1/ru unknown
- 2017-11-16 CA CA3043577A patent/CA3043577A1/en active Pending
- 2017-11-16 AU AU2017362067A patent/AU2017362067B2/en active Active
- 2017-11-16 BR BR112019009656A patent/BR112019009656A2/pt unknown
- 2017-11-16 EP EP17809387.8A patent/EP3541427B1/en active Active
- 2017-11-16 HR HRP20230349TT patent/HRP20230349T1/hr unknown
- 2017-11-16 PL PL17809387.8T patent/PL3541427T3/pl unknown
- 2017-11-16 FI FIEP17809387.8T patent/FI3541427T3/fi active
- 2017-11-16 ES ES17809387T patent/ES2941790T3/es active Active
- 2017-11-16 US US16/349,419 patent/US20240108736A1/en active Pending
- 2017-11-16 PT PT178093878T patent/PT3541427T/pt unknown
- 2017-11-16 WO PCT/IB2017/057155 patent/WO2018092048A1/en active Search and Examination
- 2017-11-16 DK DK17809387.8T patent/DK3541427T3/da active
- 2017-11-16 MX MX2019005657A patent/MX2019005657A/es unknown
- 2017-11-16 JP JP2019524935A patent/JP7208136B2/ja active Active
- 2017-11-16 KR KR1020237038228A patent/KR20230159714A/ko active Application Filing
- 2017-11-16 CN CN201780070069.3A patent/CN109982719B/zh active Active
- 2017-11-16 KR KR1020197013893A patent/KR20190084975A/ko not_active Application Discontinuation
-
2019
- 2019-05-13 IL IL266593A patent/IL266593B/en unknown
- 2019-05-15 MX MX2023004647A patent/MX2023004647A/es unknown
-
2022
- 2022-08-25 JP JP2022134497A patent/JP7467548B2/ja active Active
-
2023
- 2023-10-11 AU AU2023248123A patent/AU2023248123A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HRP20230349T1 (hr) | 2023-06-09 |
IL266593A (en) | 2019-07-31 |
JP7208136B2 (ja) | 2023-01-18 |
JP7467548B2 (ja) | 2024-04-15 |
GB2556055B (en) | 2022-03-23 |
JP2022169715A (ja) | 2022-11-09 |
BR112019009656A2 (pt) | 2019-09-17 |
AU2017362067A1 (en) | 2019-06-06 |
EP4242240A2 (en) | 2023-09-13 |
WO2018092048A1 (en) | 2018-05-24 |
FI3541427T3 (fi) | 2023-04-21 |
KR20230159714A (ko) | 2023-11-21 |
EP4242240A3 (en) | 2023-11-22 |
DK3541427T3 (da) | 2023-04-03 |
AU2023248123A1 (en) | 2023-11-02 |
GB2556055A (en) | 2018-05-23 |
PL3541427T3 (pl) | 2023-05-08 |
AU2017362067B2 (en) | 2023-07-20 |
MX2023004647A (es) | 2023-05-18 |
CA3043577A1 (en) | 2018-05-24 |
US20240108736A1 (en) | 2024-04-04 |
KR20190084975A (ko) | 2019-07-17 |
EP3541427B1 (en) | 2023-01-11 |
IL266593B (en) | 2022-02-01 |
ES2941790T3 (es) | 2023-05-25 |
MX2019005657A (es) | 2019-07-04 |
EP3541427A1 (en) | 2019-09-25 |
PT3541427T (pt) | 2023-04-17 |
HUE061518T2 (hu) | 2023-07-28 |
CN109982719A (zh) | 2019-07-05 |
JP2019535710A (ja) | 2019-12-12 |
CN117883590A (zh) | 2024-04-16 |
CN109982719B (zh) | 2024-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124055T1 (el) | Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1121299T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201991196A1 (ru) | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов | |
SA517381167B1 (ar) | عامل علاجي مستحث للسمية الخلوية | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
CY1124529T1 (el) | Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου | |
EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA202090414A1 (ru) | Соединения и их применение | |
EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний |